Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 199

1.

A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial.

Facon T, Dimopoulos MA, Meuleman N, Belch A, Mohty M, Chen WM, Kim K, Zamagni E, Rodriguez-Otero P, Renwick W, Rose C, Tempescul A, Boyle E, Manier S, Attal M, Moreau P, Macro M, Leleu X, Lorraine Chretien M, Ludwig H, Guo S, Sturniolo M, Tinel A, Silvia Monzini M, Costa B, Houck V, Hulin C, Yves Mary J.

Leukemia. 2019 Aug 19. doi: 10.1038/s41375-019-0539-0. [Epub ahead of print]

PMID:
31427722
2.

Bortezomib retreatment for relapsed and refractory multiple myeloma in real-world clinical practice.

Hulin C, de la Rubia J, Dimopoulos MA, Terpos E, Katodritou E, Hungria V, De Samblanx H, Stoppa AM, Aagesen J, Sargin D, Sioni A, Belch A, Diels J, Olie RA, Robinson D Jr, Potamianou A, van de Velde H, Delforge M.

Health Sci Rep. 2018 Dec 7;2(1):e104. doi: 10.1002/hsr2.104. eCollection 2019 Jan.

3.

Pharmacokinetics and Exposure-Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple Myeloma.

Xu XS, Dimopoulos MA, Sonneveld P, Ho PJ, Belch A, Leiba M, Capra M, Gomez D, Medvedova E, Iida S, Min CK, Schecter J, Jansson R, Zhang L, Sun YN, Clemens PL.

Adv Ther. 2018 Nov;35(11):1859-1872. doi: 10.1007/s12325-018-0815-9. Epub 2018 Oct 29.

4.

Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX.

Dimopoulos MA, San-Miguel J, Belch A, White D, Benboubker L, Cook G, Leiba M, Morton J, Ho PJ, Kim K, Takezako N, Moreau P, Kaufman JL, Sutherland HJ, Lalancette M, Magen H, Iida S, Kim JS, Prince HM, Cochrane T, Oriol A, Bahlis NJ, Chari A, O'Rourke L, Wu K, Schecter JM, Casneuf T, Chiu C, Soong D, Sasser AK, Khokhar NZ, Avet-Loiseau H, Usmani SZ.

Haematologica. 2018 Dec;103(12):2088-2096. doi: 10.3324/haematol.2018.194282. Epub 2018 Sep 20.

5.

Bortezomib-based therapy for relapsed/refractory multiple myeloma in real-world medical practice.

Terpos E, Katodritou E, de la Rubia J, Hungria V, Hulin C, Roussou M, Delforge M, Bries G, Stoppa AM, Aagesen J, Sargin D, Belch A, Ahlberg L, Diels J, Olie RA, Robinson D Jr, Spencer M, Potamianou A, van de Velde H, Dimopoulos MA.

Eur J Haematol. 2018 Oct;101(4):556-565. doi: 10.1111/ejh.13147. Epub 2018 Sep 5.

PMID:
30027641
6.

A predictive model for risk of early grade ≥ 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial.

Dumontet C, Hulin C, Dimopoulos MA, Belch A, Dispenzieri A, Ludwig H, Rodon P, Van Droogenbroeck J, Qiu L, Cavo M, Van de Velde A, Lahuerta JJ, Allangba O, Lee JH, Boyle E, Perrot A, Moreau P, Manier S, Attal M, Roussel M, Mohty M, Mary JY, Civet A, Costa B, Tinel A, Gaston-Mathé Y, Facon T.

Leukemia. 2018 Jun;32(6):1404-1413. doi: 10.1038/s41375-018-0133-x. Epub 2018 Apr 26.

7.

Efficacy and safety of frontline rituximab, cyclophosphamide, doxorubicin and prednisone plus bortezomib (VR-CAP) or vincristine (R-CHOP) in a subset of newly diagnosed mantle cell lymphoma patients medically eligible for transplantation in the randomized, phase 3 LYM-3002 study.

Drach J, Huang H, Samoilova O, Belch A, Farber C, Bosly A, Novak J, Zaucha J, Dascalescu A, Bunworasate U, Masliak Z, Vilchevskaya K, Robak T, Pei L, Rooney B, van de Velde H, Cavalli F.

Leuk Lymphoma. 2018 Apr;59(4):896-903. doi: 10.1080/10428194.2017.1365855. Epub 2018 Jan 17.

PMID:
29338540
8.

Comparative Efficacy of Daratumumab Monotherapy and Pomalidomide Plus Low-Dose Dexamethasone in the Treatment of Multiple Myeloma: A Matching Adjusted Indirect Comparison.

Van Sanden S, Ito T, Diels J, Vogel M, Belch A, Oriol A.

Oncologist. 2018 Mar;23(3):279-287. doi: 10.1634/theoncologist.2017-0103. Epub 2017 Nov 30.

9.

Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma.

Facon T, Dimopoulos MA, Dispenzieri A, Catalano JV, Belch A, Cavo M, Pinto A, Weisel K, Ludwig H, Bahlis NJ, Banos A, Tiab M, Delforge M, Cavenagh JD, Geraldes C, Lee JJ, Chen C, Oriol A, De La Rubia J, White D, Binder D, Lu J, Anderson KC, Moreau P, Attal M, Perrot A, Arnulf B, Qiu L, Roussel M, Boyle E, Manier S, Mohty M, Avet-Loiseau H, Leleu X, Ervin-Haynes A, Chen G, Houck V, Benboubker L, Hulin C.

Blood. 2018 Jan 18;131(3):301-310. doi: 10.1182/blood-2017-07-795047. Epub 2017 Nov 17.

10.

Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth.

Dimopoulos MA, Lonial S, White D, Moreau P, Palumbo A, San-Miguel J, Shpilberg O, Anderson K, Grosicki S, Spicka I, Walter-Croneck A, Magen H, Mateos MV, Belch A, Reece D, Beksac M, Bleickardt E, Poulart V, Sheng J, Sy O, Katz J, Singhal A, Richardson P.

Br J Haematol. 2017 Sep;178(6):896-905. doi: 10.1111/bjh.14787. Epub 2017 Jul 5.

11.

MS4A4A: a novel cell surface marker for M2 macrophages and plasma cells.

Sanyal R, Polyak MJ, Zuccolo J, Puri M, Deng L, Roberts L, Zuba A, Storek J, Luider JM, Sundberg EM, Mansoor A, Baigorri E, Chu MP, Belch AR, Pilarski LM, Deans JP.

Immunol Cell Biol. 2017 Aug;95(7):611-619. doi: 10.1038/icb.2017.18. Epub 2017 Mar 17.

PMID:
28303902
12.

Modified tube gastropexy using a mushroom-tipped silicone catheter for management of gastric dilatation-volvulus in dogs.

Belch A, Rubinos C, Barnes DC, Nelissen P.

J Small Anim Pract. 2017 Feb;58(2):79-88. doi: 10.1111/jsap.12615.

PMID:
28160305
13.

Skeletal muscle density is an independent predictor of diffuse large B-cell lymphoma outcomes treated with rituximab-based chemoimmunotherapy.

Chu MP, Lieffers J, Ghosh S, Belch A, Chua NS, Fontaine A, Sangha R, Turner RA, Baracos VE, Sawyer MB.

J Cachexia Sarcopenia Muscle. 2017 Apr;8(2):298-304. doi: 10.1002/jcsm.12161. Epub 2016 Nov 21.

14.

Comparison of the use of LigaSure versus a standard technique for tonsillectomy in dogs.

Belch A, Matiasovic M, Rasotto R, Demetriou J.

Vet Rec. 2017 Feb 25;180(8):196. doi: 10.1136/vr.103873. Epub 2016 Nov 3.

PMID:
27811051
15.

Addressing heterogeneity of individual blood cancers: the need for single cell analysis.

Chu MP, Kriangkum J, Venner CP, Sandhu I, Hewitt J, Belch AR, Pilarski LM.

Cell Biol Toxicol. 2017 Apr;33(2):83-97. doi: 10.1007/s10565-016-9367-4. Epub 2016 Oct 19. Review.

PMID:
27761761
16.

FGFR3 preferentially colocalizes with IGH in the interphase nucleus of multiple myeloma patient B-cells when FGFR3 is located outside of CT4.

Martin LD, Harizanova J, Mai S, Belch AR, Pilarski LM.

Genes Chromosomes Cancer. 2016 Dec;55(12):962-974. doi: 10.1002/gcc.22394. Epub 2016 Aug 11.

PMID:
27509849
17.

Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST Trial.

Hulin C, Belch A, Shustik C, Petrucci MT, Dührsen U, Lu J, Song K, Rodon P, Pégourié B, Garderet L, Hunter H, Azais I, Eek R, Gisslinger H, Macro M, Dakhil S, Goncalves C, LeBlanc R, Romeril K, Royer B, Doyen C, Leleu X, Offner F, Leupin N, Houck V, Chen G, Ervin-Haynes A, Dimopoulos MA, Facon T.

J Clin Oncol. 2016 Oct 20;34(30):3609-3617. doi: 10.1200/JCO.2016.66.7295.

PMID:
27325857
18.

Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma.

Usmani SZ, Weiss BM, Plesner T, Bahlis NJ, Belch A, Lonial S, Lokhorst HM, Voorhees PM, Richardson PG, Chari A, Sasser AK, Axel A, Feng H, Uhlar CM, Wang J, Khan I, Ahmadi T, Nahi H.

Blood. 2016 Jul 7;128(1):37-44. doi: 10.1182/blood-2016-03-705210. Epub 2016 May 23.

19.

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.

Lonial S, Weiss BM, Usmani SZ, Singhal S, Chari A, Bahlis NJ, Belch A, Krishnan A, Vescio RA, Mateos MV, Mazumder A, Orlowski RZ, Sutherland HJ, Bladé J, Scott EC, Oriol A, Berdeja J, Gharibo M, Stevens DA, LeBlanc R, Sebag M, Callander N, Jakubowiak A, White D, de la Rubia J, Richardson PG, Lisby S, Feng H, Uhlar CM, Khan I, Ahmadi T, Voorhees PM.

Lancet. 2016 Apr 9;387(10027):1551-1560. doi: 10.1016/S0140-6736(15)01120-4. Epub 2016 Jan 7.

PMID:
26778538
20.

Cost-effectiveness of lenalidomide plus dexamethasone vs. bortezomib plus melphalan and prednisone in transplant-ineligible U.S. patients with newly-diagnosed multiple myeloma.

Usmani SZ, Cavenagh JD, Belch AR, Hulin C, Basu S, White D, Nooka A, Ervin-Haynes A, Yiu W, Nagarwala Y, Berger A, Pelligra CG, Guo S, Binder G, Gibson CJ, Facon T.

J Med Econ. 2016;19(3):243-58. doi: 10.3111/13696998.2015.1115407. Epub 2015 Nov 17.

PMID:
26517601
21.

Single-Cell Analysis and Next-Generation Immuno-Sequencing Show That Multiple Clones Persist in Patients with Chronic Lymphocytic Leukemia.

Kriangkum J, Motz SN, Mack T, Beiggi S, Baigorri E, Kuppusamy H, Belch AR, Johnston JB, Pilarski LM.

PLoS One. 2015 Sep 9;10(9):e0137232. doi: 10.1371/journal.pone.0137232. eCollection 2015.

22.

Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial.

Weisel K, Dimopoulos M, Song KW, Moreau P, Palumbo A, Belch A, Schey S, Sonneveld P, Sternas L, Yu X, Amatya R, Gibson CJ, Zaki M, Jacques C, San Miguel J.

Clin Lymphoma Myeloma Leuk. 2015 Sep;15(9):519-30. doi: 10.1016/j.clml.2015.05.007. Epub 2015 Jun 6.

PMID:
26149712
23.

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.

Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, Walter-Croneck A, Moreau P, Mateos MV, Magen H, Belch A, Reece D, Beksac M, Spencer A, Oakervee H, Orlowski RZ, Taniwaki M, Röllig C, Einsele H, Wu KL, Singhal A, San-Miguel J, Matsumoto M, Katz J, Bleickardt E, Poulart V, Anderson KC, Richardson P; ELOQUENT-2 Investigators.

N Engl J Med. 2015 Aug 13;373(7):621-31. doi: 10.1056/NEJMoa1505654. Epub 2015 Jun 2.

24.

Skeletal muscle radio-density is an independent predictor of response and outcomes in follicular lymphoma treated with chemoimmunotherapy.

Chu MP, Lieffers J, Ghosh S, Belch AR, Chua NS, Fontaine A, Sangha R, Turner AR, Baracos VE, Sawyer MB.

PLoS One. 2015 Jun 1;10(6):e0127589. doi: 10.1371/journal.pone.0127589. eCollection 2015.

25.

Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report.

Palumbo A, Bringhen S, Mateos MV, Larocca A, Facon T, Kumar SK, Offidani M, McCarthy P, Evangelista A, Lonial S, Zweegman S, Musto P, Terpos E, Belch A, Hajek R, Ludwig H, Stewart AK, Moreau P, Anderson K, Einsele H, Durie BG, Dimopoulos MA, Landgren O, San Miguel JF, Richardson P, Sonneveld P, Rajkumar SV.

Blood. 2015 Mar 26;125(13):2068-74. doi: 10.1182/blood-2014-12-615187. Epub 2015 Jan 27. Erratum in: Blood. 2016 Mar 3;127(9):1213. Erratum in: Blood. 2016 Mar 3;127(9):1213. Blood. 2016 Aug 18;128(7):1020.

26.

Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myeloma.

Song KW, Dimopoulos MA, Weisel KC, Moreau P, Palumbo A, Belch A, Schey S, Sonneveld P, Sternas L, Yu X, Amatya R, Monzini MS, Zaki M, Jacques C, San Miguel J.

Haematologica. 2015 Feb;100(2):e63-7. doi: 10.3324/haematol.2014.112557. Epub 2014 Nov 25. No abstract available.

27.

What is your diagnosis? Fracture of the distal diaphysis with pronounced lateral displacement of the lateral malleolus.

Belch AC, Hammond GJ, Brannan NL, Marshall W.

J Am Vet Med Assoc. 2014 Nov 15;245(10):1095-7. doi: 10.2460/javma.245.10.1095. No abstract available.

PMID:
25356706
28.

Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma.

Toumishey E, Prasad A, Dueck G, Chua N, Finch D, Johnston J, van der Jagt R, Stewart D, White D, Belch A, Reiman T.

Cancer. 2015 Mar 1;121(5):716-23. doi: 10.1002/cncr.29103. Epub 2014 Oct 29.

29.

Thalidomide-prednisone maintenance following autologous stem cell transplant for multiple myeloma: effect on thrombin generation and procoagulant markers in NCIC CTG MY.10.

Kovacs MJ, Davies GA, Chapman JA, Bahlis N, Voralia M, Roy J, Kouroukis CT, Chen C, Belch A, Reece D, Zhu L, Meyer RM, Shepherd L, Stewart KA.

Br J Haematol. 2015 Feb;168(4):511-7. doi: 10.1111/bjh.13176. Epub 2014 Oct 10.

PMID:
25302852
30.

Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.

Benboubker L, Dimopoulos MA, Dispenzieri A, Catalano J, Belch AR, Cavo M, Pinto A, Weisel K, Ludwig H, Bahlis N, Banos A, Tiab M, Delforge M, Cavenagh J, Geraldes C, Lee JJ, Chen C, Oriol A, de la Rubia J, Qiu L, White DJ, Binder D, Anderson K, Fermand JP, Moreau P, Attal M, Knight R, Chen G, Van Oostendorp J, Jacques C, Ervin-Haynes A, Avet-Loiseau H, Hulin C, Facon T; FIRST Trial Team.

N Engl J Med. 2014 Sep 4;371(10):906-17. doi: 10.1056/NEJMoa1402551.

31.

Aberrant posttranscriptional processing of hyaluronan synthase 1 in malignant transformation and tumor progression.

Adamia S, Kriangkum J, Belch AR, Pilarski LM.

Adv Cancer Res. 2014;123:67-94. doi: 10.1016/B978-0-12-800092-2.00003-4. Review.

PMID:
25081526
32.

Genotyping single nucleotide polymorphisms in human genomic DNA with an automated and self-contained PCR cassette.

Manage DP, Ma L, Lauzon J, Howell A, Belch AR, Mackey JR, Pilarski LM.

J Mol Diagn. 2014 Sep;16(5):550-557. doi: 10.1016/j.jmoldx.2014.04.004. Epub 2014 Jul 2.

PMID:
24998937
33.

Inherited polymorphisms in hyaluronan synthase 1 predict risk of systemic B-cell malignancies but not of breast cancer.

Kuppusamy H, Ogmundsdottir HM, Baigorri E, Warkentin A, Steingrimsdottir H, Haraldsdottir V, Mant MJ, Mackey J, Johnston JB, Adamia S, Belch AR, Pilarski LM.

PLoS One. 2014 Jun 20;9(6):e100691. doi: 10.1371/journal.pone.0100691. eCollection 2014.

34.

Active idiotypic vaccination versus control immunotherapy for follicular lymphoma.

Levy R, Ganjoo KN, Leonard JP, Vose JM, Flinn IW, Ambinder RF, Connors JM, Berinstein NL, Belch AR, Bartlett NL, Nichols C, Emmanouilides CE, Timmerman JM, Gregory SA, Link BK, Inwards DJ, Freedman AS, Matous JV, Robertson MJ, Kunkel LA, Ingolia DE, Gentles AJ, Liu CL, Tibshirani R, Alizadeh AA, Denney DW Jr.

J Clin Oncol. 2014 Jun 10;32(17):1797-803. doi: 10.1200/JCO.2012.43.9273. Epub 2014 May 5.

35.

A three-dimensional tissue culture model to study primary human bone marrow and its malignancies.

Parikh MR, Belch AR, Pilarski LM, Kirshner J.

J Vis Exp. 2014 Mar 8;(85). doi: 10.3791/50947.

36.

Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study.

Richardson PG, Siegel DS, Vij R, Hofmeister CC, Baz R, Jagannath S, Chen C, Lonial S, Jakubowiak A, Bahlis N, Song K, Belch A, Raje N, Shustik C, Lentzsch S, Lacy M, Mikhael J, Matous J, Vesole D, Chen M, Zaki MH, Jacques C, Yu Z, Anderson KC.

Blood. 2014 Mar 20;123(12):1826-32. doi: 10.1182/blood-2013-11-538835. Epub 2014 Jan 13. Erratum in: Blood. 2014 May 15;123(20):3208-9.

37.

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.

Miguel JS, Weisel K, Moreau P, Lacy M, Song K, Delforge M, Karlin L, Goldschmidt H, Banos A, Oriol A, Alegre A, Chen C, Cavo M, Garderet L, Ivanova V, Martinez-Lopez J, Belch A, Palumbo A, Schey S, Sonneveld P, Yu X, Sternas L, Jacques C, Zaki M, Dimopoulos M.

Lancet Oncol. 2013 Oct;14(11):1055-1066. doi: 10.1016/S1470-2045(13)70380-2. Epub 2013 Sep 3.

PMID:
24007748
38.

Frequent occurrence of highly expanded but unrelated B-cell clones in patients with multiple myeloma.

Kriangkum J, Motz SN, Debes Marun CS, Lafarge ST, Gibson SB, Venner CP, Johnston JB, Belch AR, Pilarski LM.

PLoS One. 2013 May 28;8(5):e64927. doi: 10.1371/journal.pone.0064927. Print 2013.

39.

Efficacy and safety of busulfan-based conditioning regimens for multiple myeloma.

Reece D, Song K, LeBlanc R, Mezzi K, Olujohungbe A, White D, Zaman F, Belch A.

Oncologist. 2013;18(5):611-8. doi: 10.1634/theoncologist.2012-0384. Epub 2013 Apr 29. Review.

40.

The systemic cytokine environment is permanently altered in multiple myeloma.

Zheng MM, Zhang Z, Bemis K, Belch AR, Pilarski LM, Shively JE, Kirshner J.

PLoS One. 2013;8(3):e58504. doi: 10.1371/journal.pone.0058504. Epub 2013 Mar 27.

41.

Aberrant splicing, hyaluronan synthases and intracellular hyaluronan as drivers of oncogenesis and potential drug targets.

Adamia S, Pilarski PM, Belch AR, Pilarski LM.

Curr Cancer Drug Targets. 2013 May;13(4):347-61. Review.

PMID:
23517594
42.

Differential nuclear organization of translocation-prone genes in nonmalignant B cells from patients with t(14;16) as compared with t(4;14) or t(11;14) myeloma.

Martin LD, Harizanova J, Righolt CH, Zhu G, Mai S, Belch AR, Pilarski LM.

Genes Chromosomes Cancer. 2013 Jun;52(6):523-37. doi: 10.1002/gcc.22049. Epub 2013 Mar 5.

PMID:
23460268
43.

Gene methylation and silencing of SOCS3 in mantle cell lymphoma.

Molavi O, Wang P, Zak Z, Gelebart P, Belch A, Lai R.

Br J Haematol. 2013 May;161(3):348-56. doi: 10.1111/bjh.12262. Epub 2013 Feb 22.

PMID:
23432547
44.

Alteration of introns in a hyaluronan synthase 1 (HAS1) minigene convert Pre-mRNA [corrected] splicing to the aberrant pattern in multiple myeloma (MM): MM patients harbor similar changes.

Kriangkum J, Warkentin A, Belch AR, Pilarski LM.

PLoS One. 2013;8(1):e53469. doi: 10.1371/journal.pone.0053469. Epub 2013 Jan 3. Erratum in: PLoS One. 2013;8(4). doi:10.1371/annotation/9984da27-0e7f-4c7f-bcd3-bef1a4c0be87. Warkinton, Amanda [corrected to Warkentin, Amanda].

45.

A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial.

Stewart AK, Trudel S, Bahlis NJ, White D, Sabry W, Belch A, Reiman T, Roy J, Shustik C, Kovacs MJ, Rubinger M, Cantin G, Song K, Tompkins KA, Marcellus DC, Lacy MQ, Sussman J, Reece D, Brundage M, Harnett EL, Shepherd L, Chapman JA, Meyer RM.

Blood. 2013 Feb 28;121(9):1517-23. doi: 10.1182/blood-2012-09-451872. Epub 2013 Jan 7.

46.

Impact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia: results of sequential cancer and leukemia group B studies.

Woyach JA, Ruppert AS, Rai K, Lin TS, Geyer S, Kolitz J, Appelbaum FR, Tallman MS, Belch AR, Morrison VA, Larson RA, Byrd JC.

J Clin Oncol. 2013 Feb 1;31(4):440-7. doi: 10.1200/JCO.2011.41.5646. Epub 2012 Dec 10.

47.

Lenalidomide plus melphalan without prednisone for previously untreated older patients with multiple myeloma: a phase II trial.

White DJ, Bahlis NJ, Marcellus DC, Belch A, Stewart AK, Chen C, Kovacs MJ, Macdonald DA, Reece DE, Reiman T, Harnett E, Meyer RM, Chapman JA, Couban S.

Clin Lymphoma Myeloma Leuk. 2013 Feb;13(1):19-24. doi: 10.1016/j.clml.2012.08.009. Epub 2012 Nov 7.

PMID:
23141150
48.

In non-transplant patients with multiple myeloma, the pre-treatment level of clonotypic cells predicts event-free survival.

Thulien KJ, Belch AR, Reiman T, Pilarski LM.

Mol Cancer. 2012 Oct 19;11:78. doi: 10.1186/1476-4598-11-78.

49.

The impact of initial fludarabine therapy on transformation to Richter syndrome or prolymphocytic leukemia in patients with chronic lymphocytic leukemia: analysis of an intergroup trial (CALGB 9011).

Solh M, Rai KR, Peterson BL, Kolitz JE, Appelbaum FR, Tallman MS, Belch A, Larson RA, Morrison VA.

Leuk Lymphoma. 2013 Feb;54(2):252-4. doi: 10.3109/10428194.2012.710327. Epub 2012 Sep 8.

50.

An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib.

Vij R, Siegel DS, Jagannath S, Jakubowiak AJ, Stewart AK, McDonagh K, Bahlis N, Belch A, Kunkel LA, Wear S, Wong AF, Wang M.

Br J Haematol. 2012 Sep;158(6):739-48. doi: 10.1111/j.1365-2141.2012.09232.x. Epub 2012 Jul 30.

Supplemental Content

Support Center